UY32180A - Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1) - Google Patents
Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)Info
- Publication number
- UY32180A UY32180A UY0001032180A UY32180A UY32180A UY 32180 A UY32180 A UY 32180A UY 0001032180 A UY0001032180 A UY 0001032180A UY 32180 A UY32180 A UY 32180A UY 32180 A UY32180 A UY 32180A
- Authority
- UY
- Uruguay
- Prior art keywords
- trpv1
- vanilloid
- receiver antagonists
- potential transitory
- transitory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula (I) o sales, solvatos, prodrogas o sales de prodrogas farmacéuticamente aceptables de éstos, o sus combinaciones.donde R1, R2, R3, R4 y m tienen los valores que se definen en la memoria descriptiva. Composiciones que comprenden estos compuestos y métodos para tratar afecciones y trastonos usando dichos compuestos y dichas composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10636908P | 2008-10-17 | 2008-10-17 | |
US22007509P | 2009-06-24 | 2009-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32180A true UY32180A (es) | 2010-05-31 |
Family
ID=41571121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032180A UY32180A (es) | 2008-10-17 | 2009-10-15 | Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1) |
Country Status (11)
Country | Link |
---|---|
US (1) | US8604053B2 (es) |
EP (1) | EP2352726A1 (es) |
JP (1) | JP2012505907A (es) |
CN (1) | CN102186836A (es) |
AR (1) | AR073631A1 (es) |
CA (1) | CA2737768A1 (es) |
MX (1) | MX2011004081A (es) |
PA (1) | PA8845601A1 (es) |
TW (1) | TW201020236A (es) |
UY (1) | UY32180A (es) |
WO (1) | WO2010045401A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8609692B2 (en) * | 2008-10-17 | 2013-12-17 | Abbvie Inc. | TRPV1 antagonists |
US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
MX351165B (es) * | 2011-03-25 | 2017-10-04 | Abbvie Inc | Antagonistas de trpv1. |
US8969325B2 (en) | 2011-12-19 | 2015-03-03 | Abbvie Inc. | TRPV1 antagonists |
US8859584B2 (en) | 2011-12-19 | 2014-10-14 | Abbvie, Inc. | TRPV1 antagonists |
EP2828253A1 (en) * | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
JP6115303B2 (ja) * | 2012-05-18 | 2017-04-19 | Jnc株式会社 | 隣接基としてカルボニル基を有するフェノール化合物およびその用途 |
US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
US9981972B2 (en) | 2014-05-22 | 2018-05-29 | Abide Therapeutics, Inc. | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets |
US10336709B2 (en) | 2015-10-02 | 2019-07-02 | Abide Therapeutics, Inc | Lp-PLA2 inhibitors |
AU2018297270B2 (en) * | 2017-07-06 | 2024-02-15 | Dignity Health | Novel treatment for hot flushes |
CN108929270B (zh) * | 2018-08-15 | 2021-06-08 | 上海罕道医药科技有限公司 | 一种药物中间体双取代含氮杂环的胺类化合物的合成 |
EP3917916A4 (en) | 2019-01-30 | 2022-12-14 | Montelino Therapeutics, Inc. | BIFUNCTIONAL COMPOUNDS AND METHODS FOR TARGETING ANDROGEN RECEPTOR UBIQUITINATION |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
MX2022002017A (es) | 2019-08-23 | 2022-03-11 | Mochida Pharm Co Ltd | Metodo para producir derivado de heterociclideno acetamida. |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
WO2024102810A1 (en) | 2022-11-08 | 2024-05-16 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
EP1658269B1 (en) * | 2003-06-12 | 2008-10-22 | Abbott Laboratories | Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
US7015233B2 (en) | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
US7651514B2 (en) | 2003-12-11 | 2010-01-26 | Boston Scientific Scimed, Inc. | Nose rider improvement for filter exchange and methods of use |
US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
CA2588909A1 (en) * | 2004-11-24 | 2006-06-22 | Abbott Laboratories | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
KR20080064972A (ko) * | 2005-10-07 | 2008-07-10 | 그렌마크 파머수티칼스 에스. 아. | 치환된 벤조융합 유도체 및 이의 바닐로이드 수용체리간드로서의 용도 |
NZ567358A (en) | 2005-10-28 | 2011-10-28 | Abbott Lab | Indazole derivatives that inhibit TRPV1 receptor |
JP2009534399A (ja) * | 2006-04-18 | 2009-09-24 | アボット・ラボラトリーズ | バニロイド受容体サブタイプ1型(vr1)の拮抗薬およびその使用 |
WO2008040360A2 (en) | 2006-10-04 | 2008-04-10 | Neurokey A/S | Use of hypothermia inducing drugs to treat ischemia |
WO2008040361A2 (en) | 2006-10-04 | 2008-04-10 | Neurokey A/S | Use of a combination of hypothermia inducing drugs |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008059339A2 (en) * | 2006-11-13 | 2008-05-22 | Glenmark Pharmaceuticals S.A. | Isoquinoline derivatives as vanilloid receptor modulators |
EP2450346A1 (en) | 2006-12-20 | 2012-05-09 | Abbott Laboratories | Antagonists of the TRPV1 receptor and uses thereof |
KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
WO2008110863A1 (en) * | 2007-03-15 | 2008-09-18 | Glenmark Pharmaceuticals S.A. | Indazole derivatives and their use as vanilloid receptor ligands |
KR20100012031A (ko) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
UY31406A1 (es) * | 2007-10-19 | 2009-05-29 | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". | |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
US8609692B2 (en) * | 2008-10-17 | 2013-12-17 | Abbvie Inc. | TRPV1 antagonists |
-
2009
- 2009-10-15 TW TW098134972A patent/TW201020236A/zh unknown
- 2009-10-15 US US12/579,821 patent/US8604053B2/en active Active
- 2009-10-15 EP EP09740591A patent/EP2352726A1/en not_active Withdrawn
- 2009-10-15 MX MX2011004081A patent/MX2011004081A/es not_active Application Discontinuation
- 2009-10-15 JP JP2011532227A patent/JP2012505907A/ja active Pending
- 2009-10-15 UY UY0001032180A patent/UY32180A/es not_active Application Discontinuation
- 2009-10-15 CN CN2009801412472A patent/CN102186836A/zh active Pending
- 2009-10-15 PA PA20098845601A patent/PA8845601A1/es unknown
- 2009-10-15 CA CA2737768A patent/CA2737768A1/en not_active Abandoned
- 2009-10-15 WO PCT/US2009/060732 patent/WO2010045401A1/en active Application Filing
- 2009-10-15 AR ARP090103975A patent/AR073631A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2011004081A (es) | 2011-05-31 |
AR073631A1 (es) | 2010-11-17 |
US8604053B2 (en) | 2013-12-10 |
CA2737768A1 (en) | 2010-04-22 |
TW201020236A (en) | 2010-06-01 |
WO2010045401A1 (en) | 2010-04-22 |
EP2352726A1 (en) | 2011-08-10 |
CN102186836A (zh) | 2011-09-14 |
JP2012505907A (ja) | 2012-03-08 |
US20100137360A1 (en) | 2010-06-03 |
PA8845601A1 (es) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32180A (es) | Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1) | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
DOP2008000060A (es) | Compuestos novedosos como ligandos del receptor de canabinoides y usos de los mismo. | |
CR11036A (es) | Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos | |
AR062875A1 (es) | Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos | |
NI200700319A (es) | Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento. | |
EA201891615A1 (ru) | Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY30606A1 (es) | Derivados 2 y n sustituidos de la 2-metil propionamida, sus tautomeros y sales farmacéuticamente aceptables, composiciones y aplicaciones | |
UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
DOP2011000217A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
HN2008001464A (es) | Formulaciones para administrcion parenteral de compuestos y sus usos | |
DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
MX2010007392A (es) | Antagonistas de trpa1. | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20180919 |